|
1
|
Choo QL, Kuo G, Weiner AJ, Overby LR,
Bradley DW and Houghton M: Isolation of a cDNA clone derived from a
blood-borne non-A, non-B viral hepatitis genome. Science.
244:359–362. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hajarizadeh B, Grebely J and Dore GJ:
Epidemiology and natural history of HCV infection. Nat Rev
Gastroenterol Hepatol. 10:553–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gower E, Estes C, Hindman S,
Razavi-Shearer K and Razavi H: Global epidemiology and genotype
distribution of the hepatitis C virus infection. J Hepatol. 61 1
Suppl:S45–S57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lavanchy D: Evolving epidemiology of
hepatitis C virus. Clin Microbiol Infect. 17:107–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thein HH, Yi Q, Dore GJ and Krahn MD:
Estimation of stage-specific fibrosis progression rates in chronic
hepatitis C virus infection: A meta-analysis and meta-regression.
Hepatology. 48:418–431. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tyagi I and Koirala J: Hepatitis C.
StatPearls Publishing; Treasure Island, FL: 2017
|
|
7
|
Zhu GQ, Zou ZL, Zheng JN, Chen DZ, Zou TT,
Shi KQ and Zheng MH: Systematic review and network meta-analysis of
randomized controlled trials: Comparative effectiveness and safety
of direct-acting antiviral agents for treatment-naive hepatitis C
Genotype 1. Medicine (Baltimore). 95:e30042016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lawitz E, Matusow G, DeJesus E, Yoshida
EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G,
Sheikh A, et al: Simeprevir plus sofosbuvir in patients with
chronic hepatitis C virus genotype 1 infection and cirrhosis: A
Phase 3 study (OPTIMIST-2). Hepatology. 64:360–369. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mizokami M, Yokosuka O, Takehara T,
Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F,
Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination
with and without ribavirin for 12 weeks in treatment-naive and
previously treated Japanese patients with genotype 1 hepatitis C:
An open-label, randomised, phase 3 trial. Lancet Infect Dis.
15:645–653. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumada H, Chayama K, Rodrigues L Jr,
Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka
K, et al: Randomized phase 3 trial of
ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype
1b-infected japanese patients with or without cirrhosis.
Hepatology. 62:1037–1046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chayama K, Notsumata K, Kurosaki M, Sato
K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA and
Kumada H: Randomized trial of interferon- and ribavirin-free
ombitasvir/paritaprevir/ritonavir in treatment-experienced
hepatitis c virus-infected patients. Hepatology. 61:1523–1532.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Younossi ZM, Stepanova M, Nader F, Lam B
and Hunt S: The patient's journey with chronic hepatitis C from
interferon plus ribavirin to interferon- and ribavirin-free
regimens: A study of health-related quality of life. Aliment
Pharmacol Ther. 42:286–295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suzuki M, Ishikawa T, Sakuma A, Abe S, Abe
H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, et al:
Evaluation of the health-related quality of life using the 36-item
short form health survey in patients with chronic hepatitisis C
receiving pegylated interferon/ribavirin/telaprevir triple
treatment. Exp Ther Med. 12:3353–3358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sulkowski MS, Vargas HE, Di Bisceglie AM,
Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS,
et al: Effectiveness of simeprevir plus sofosbuvir, with or without
ribavirin, in real-world patients with HCV genotype 1 infection.
Gastroenterology. 150:419–429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Younossi ZM, Stepanova M, Chan HL, Lee MH,
Yu ML, Dan YY, Choi MS and Henry L: Patient-reported outcomes in
Asian patients with chronic hepatitis C treated with ledipasvir and
sofosbuvir. Medicine (Baltimore). 95:e27022016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Younossi Z, Stepanova M, Omata M, Mizokami
M, Walters M and Hunt S: Health utilities using SF-6D scores in
Japanese patients with chronic hepatitis C treated with
sofosbuvir-based regimens in clinical trials. Health Qual Life
Outcomes. 15:252017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Youssef NF, El Kassas M, Farag A and
Shepherd A: Health-related quality of life in patients with chronic
hepatitis C receiving Sofosbuvir-based treatment, with and without
Interferon: A prospective observational study in Egypt. BMC
Gastroenterol. 17:182017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salomon JA, Wang H, Freeman MK, Vos T,
Flaxman AD, Lopez AD and Murray CJ: Healthy life expectancy for 187
countries, 1990–2010: A systematic analysis for the Global Burden
Disease Study 2010. Lancet. 380:2144–2162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spiegel BM, Younossi ZM, Hays RD, Revicki
D, Robbins S and Kanwal F: Impact of hepatitis C on health related
quality of life: A systematic review and quantitative assessment.
Hepatology. 41:790–800. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Svirtlih N, Pavic S, Terzic D, Delic D,
Simonovic J, Gvazdenovic E and Boricic I: Reduced quality of life
in patients with chronic viral liver disease as assessed by SF12
questionnaire. J Gastrointest Liver Dis. 17:405–409. 2008.
|
|
22
|
Tao T, Jiang X, Chen Y and Song Y:
Efficacy and safety of ledipasvir/sofosbuvir with and without
ribavirin in patients with chronic hepatitis C virus genotype 1
infection: A meta-analysis. Int J Infect Dis. 55:56–71. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bunchorntavakul C and Reddy KR: Review
article: The efficacy and safety of daclatasvir in the treatment of
chronic hepatitis C virus infection. Aliment Pharmacol Ther.
42:258–272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kumada H, Suzuki Y, Ikeda K, Toyota J,
Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et
al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b
infection. Hepatology. 59:2083–2091. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Santos PR and Franco Sansigolo Kerr LR:
Clinical and laboratory variables associated with quality of life
in Brazilian haemodialysis patients: A single-centre study. Rev Med
Chil. 136:1264–1271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parkash O, Iqbal R, Jafri F, Azam I and
Jafri W: Frequency of poor quality of life and predictors of health
related quality of life in cirrhosis at a tertiary care hospital
Pakistan. BMC Res Notes. 5:4462012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sterling RK, Lissen E, Clumeck N, Sola R,
Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT,
Thomas DL, et al: Development of a simple noninvasive index to
predict significant fibrosis in patients with HIV/HCV coinfection.
Hepatology. 43:1317–1325. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang DY and Friedman SL:
Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology.
56:769–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ogawa E, Furusyo N, Nomura H, Dohmen K,
Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, et
al: NS5A resistance-associated variants undermine the effectiveness
of ledipasvir and sofosbuvir for cirrhotic patients infected with
HCV genotype 1b. J Gastroenterol. 52:845–854. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Atsukawa M, Tsubota A, Koushima Y, Ikegami
T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, et al:
Efficacy and safety of ombitasvir/paritaprevir/ritonavir in
dialysis patients with genotype 1b chronic hepatitis C. Hepatol
Res. Apr 29–2017.(Epub ahead of print). View Article : Google Scholar
|
